Literature DB >> 32024976

A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome.

Shibo Jiang1, Shuai Xia2, Tianlei Ying2, Lu Lu2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32024976      PMCID: PMC7091741          DOI: 10.1038/s41423-020-0372-4

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   22.096


× No keyword cloud information.
By the end of 2019, the World Health Organization (WHO) was informed about an outbreak of pneumonia of unknown etiology in Wuhan, China. Some patients were linked to a seafood market, suggesting animal-to-human transmission, but, soon, human-to-human transmission was confirmed. The pathogen was promptly identified as a novel coronavirus belonging to lineage B betacoronaviruses that also include severe acute respiratory syndrome coronavirus (SARS-CoV), which caused a pandemic in China in 2002/2003, and bat SARS-like coronaviruses.[1] Since 2012, the outbreak of Middle East respiratory syndrome coronavirus infection starting from Saudi Arabia has resulted in 2494 confirmed cases and 858 deaths in 27 countries, posing ongoing threat to global public health (https://www.who.int/emergencies/mers-cov/en). As of 1 February 2020, there were 12,024 confirmed cases with Wuhan pneumonia and 259 deaths, of which 11,860 cases were found in Mainland China and 164 in 26 other countries and territories. The estimated case fatality rate is about 2%, which is much lower than that of SARS (9.6%), while its transmission rate (R0) is 2–3% (https://www.worldometers.info/coronavirus), similar to that of SARS (3%). Like SARS-CoV-infected individuals, patients infected with this novel betacoronavirus showed abnormal findings on chest computed tomography, along with common symptoms that include fever, cough, and myalgia, or fatigue, at the onset of illness. Still, all indications suggest that the acute respiratory syndrome of SARS is, so far, more severe than that manifested by the present pneumonia outbreak.[2] The novel coronavirus was denoted as “2019-nCoV” by WHO (https://www.who.int/emergencies/diseases/novel-coronavirus-2019) and the Wuhan pneumonia was named as “novel coronavirus-infected pneumonia (NCIP)” by Chinese scientists.[3] However, it will seem illogical if coronavirus is listed after NCIP, i.e., “novel coronavirus-infected pneumonia coronavirus (NCIP-CoV)”. Therefore, we suggest renaming NCIP as “pneumonia-associated respiratory syndrome (PARS)” and 2019-nCoV as “PARS coronavirus (PARS-CoV)”, similar to SARS-CoV, to retain equivalent terminology.
  3 in total

1.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

2.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.

Authors:  Qun Li; Xuhua Guan; Peng Wu; Xiaoye Wang; Lei Zhou; Yeqing Tong; Ruiqi Ren; Kathy S M Leung; Eric H Y Lau; Jessica Y Wong; Xuesen Xing; Nijuan Xiang; Yang Wu; Chao Li; Qi Chen; Dan Li; Tian Liu; Jing Zhao; Man Liu; Wenxiao Tu; Chuding Chen; Lianmei Jin; Rui Yang; Qi Wang; Suhua Zhou; Rui Wang; Hui Liu; Yinbo Luo; Yuan Liu; Ge Shao; Huan Li; Zhongfa Tao; Yang Yang; Zhiqiang Deng; Boxi Liu; Zhitao Ma; Yanping Zhang; Guoqing Shi; Tommy T Y Lam; Joseph T Wu; George F Gao; Benjamin J Cowling; Bo Yang; Gabriel M Leung; Zijian Feng
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 176.079

3.  An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies.

Authors:  Shibo Jiang; Lanying Du; Zhengli Shi
Journal:  Emerg Microbes Infect       Date:  2020-01-31       Impact factor: 7.163

  3 in total
  51 in total

1.  Foundation and Clinical Evaluation of a New Method for Detecting SARS-CoV-2 Antigen by Fluorescent Microsphere Immunochromatography.

Authors:  Chunyan Zhang; Lei Zhou; Kang Du; Ying Zhang; Jing Wang; Lijuan Chen; Yanning Lyu; Jun Li; Hao Liu; Junli Huo; Fei Li; Jiayi Wang; Peipei Sang; Si Lin; Yi Xiao; Kan Zhang; Kunlun He
Journal:  Front Cell Infect Microbiol       Date:  2020-11-30       Impact factor: 5.293

2.  Clinical features in coronavirus disease 2019 (COVID-19) patients with early clearance and prolonged shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA.

Authors:  Yan Zhou; Fengming Ding; Wuping Bao; Yishu Xue; Lei Han; Xue Zhang; Pengyu Zhang; Yong Ji; Dongning Yin; Aihua Bao; Shan Luo; Zengchao Xu; Jun Liu; Min Zhang
Journal:  Ann Transl Med       Date:  2021-04

Review 3.  Prevalence and mortality of lung comorbidities among patients with COVID-19: A systematic review and meta-analysis.

Authors:  Mohammed G Alkhathami; Shailesh M Advani; Adil A Abalkhail; Fahad M Alkhathami; Mohammed K Alshehri; Ebtisam E Albeashy; Jihad A Alsalamah
Journal:  Lung India       Date:  2021-03

4.  Analysis of current SARS-CoV-2 infection in a large population of blood donors evidenced that RNAemia is rare in plasma.

Authors:  Daniel Gonçalves Chaves; Maria Clara Fernandes da Silva Malta; Luciana de Souza Madeira Ferreira Boy; Aretuza Miranda Barbosa; Cinthia Neves Fonseca; Dayanne Ellen de Lima Torres; Janaína Patterson Nogueira; Hélinse Medeiros Moreira; Flávia Cristine Martineli Loureiro; Jaciane Vargas de Freitas Silva; Maísa Aparecida Ribeiro; Júnia Guimarães Mourão Cioffi; Marina Lobato Martins
Journal:  Transfusion       Date:  2021-06-10       Impact factor: 3.337

5.  Risk factors for the exacerbation of patients with 2019 Novel Coronavirus: A meta-analysis.

Authors:  Jinqiu Zhao; Xiaosong Li; Yao Gao; Wenxiang Huang
Journal:  Int J Med Sci       Date:  2020-07-06       Impact factor: 3.738

Review 6.  From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.

Authors:  Cuiqing Ma; Shan Su; Jiachao Wang; Lin Wei; Lanying Du; Shibo Jiang
Journal:  Microbes Infect       Date:  2020-05-11       Impact factor: 2.700

Review 7.  Targeting SARS-CoV-2-Platelet Interactions in COVID-19 and Vaccine-Related Thrombosis.

Authors:  Dermot Cox
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

8.  Asymptomatic and Human-to-Human Transmission of SARS-CoV-2 in a 2-Family Cluster, Xuzhou, China.

Authors:  Chunyang Li; Fang Ji; Liang Wang; Liping Wang; Jungui Hao; Mingjia Dai; Yan Liu; Xiucheng Pan; Juanjuan Fu; Li Li; Guangde Yang; Jianye Yang; Xuebing Yan; Bing Gu
Journal:  Emerg Infect Dis       Date:  2020-06-21       Impact factor: 6.883

Review 9.  New understanding of the damage of SARS-CoV-2 infection outside the respiratory system.

Authors:  Yuhao Zhang; Xiuchao Geng; Yanli Tan; Qiang Li; Can Xu; Jianglong Xu; Liangchao Hao; Zhaomu Zeng; Xianpu Luo; Fulin Liu; Hong Wang
Journal:  Biomed Pharmacother       Date:  2020-04-28       Impact factor: 7.419

10.  Comorbidities and multi-organ injuries in the treatment of COVID-19.

Authors:  Tianbing Wang; Zhe Du; Fengxue Zhu; Zhaolong Cao; Youzhong An; Yan Gao; Baoguo Jiang
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.